Press Releases

MTI Secures $3.2M USD Financing Round
News Posted On Oct 21, 2019

MTI Secures $3.2M USD Financing Round

Metabolomic Technologies Inc. (MTI) announced the successful completion of a $3.2M USD Series A raise. The company's lead product, PolypDx™, is the world's first and only urine test for colorectal cancer screening. Developed in Canada, and patented…

MTI Named BioAlberta Company of the Year
News Posted On Sep 25, 2019

MTI Named BioAlberta Company of the Year

Metabolomic Technologies was presented with the BioAlberta Company of the Year Award at the 20th Annual BioAlberta Awards Gala. This Award was presented to MTI for excellence and innovation with their flagship product, PolypDx™,  and their strong…

MTI recognized at American College of Gastroenterology
News Posted On Nov 21, 2018

MTI recognized at American College of Gastroenterology

MTI's poster entitled “Urine Metabolomic Biomarker Panel for Colorectal Cancer” was recognized as a Presidential Poster at the ACG 2018 Annual Scientific Meeting in Philadelphia. Fewer than 5% of accepted abstracts each year receive this distinction…

Alberta to assess a new screening strategy using MTI's PolypDx™
News Posted On Oct 22, 2018

Alberta to assess a new screening strategy using MTI's PolypDx™

Metabolomic Technologies Inc. today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. The…

MTI to Exhibit at ACG - Philadelphia
News Posted On Oct 07, 2018

MTI to Exhibit at ACG - Philadelphia

MTI is excited to be attending the 2018 American College of Gastroenterology Conference in Philadelphia, PA. Team members will be on site ready to discuss the first and only urine test for detection and prevention of colorectal cancer, PolypDx™.…

MTI selected to present at Falling Walls Venture in Berlin, Germany
News Posted On Nov 08, 2017

MTI selected to present at Falling Walls Venture in Berlin, Germany

Metabolomic Technologies Inc. is selected as one of 20 outstanding science based start-ups from leading international academic institutions and international venture capitalists in the Falling Walls Venture competition held in Berlin, Germany. As…

MTI Receives ASTech Outstanding Leadership in Technology Award
News Posted On Nov 03, 2017

MTI Receives ASTech Outstanding Leadership in Technology Award

Metabolomic Technologies Inc. is the 2017 recipient of the Outstanding Leadership in Technology Award from the ASTech Foundation. The ASTech Foundation award recognizes outstanding innovation in science and technology in Alberta....

Patent Granted for PolypDx™ in Europe
News Posted On Nov 01, 2017

Patent Granted for PolypDx™ in Europe

Metabolomic Technologies Inc. has been granted a patent for its PolypDx™ technology by the European Patent Office. PolypDx™ received patent approval in Japan in September, 2015, and in Australia in February, 2017. Patents are also pending in the…

MTI Appoints David Chang as New CEO
News Posted On Jun 21, 2017

MTI Appoints David Chang as New CEO

Metabolomic Technologies Inc. announces that it has appointed David Chang as Chief Executive Officer as of May 1st, 2017. Dr. Chang replaces Reg Joseph as CEO. He brings to the position 15 years experience managing SMEs and commercializing research projects.…

MTI Recipient of the 2017 ATB Catalyst Export Award
News Posted On Jun 06, 2017

MTI Recipient of the 2017 ATB Catalyst Export Award

On June 6, 2017 MTI was presented with the 2017 ATB Catalyst Export Award. The award recognizes MTI's engagement in international business and export, while achieving excellence through sustainable growth and innovation....

MTI to Exhibit at DDW - May 2017 in Chicago, IL
News Posted On May 06, 2017

MTI to Exhibit at DDW - May 2017 in Chicago, IL

MTI is excited to be attending the 2017 Digestive Disease Week Conference, May, 2017 in Chicago, IL. Team members will be on site ready to discuss our non-invasive urine-based diagnostic test for detection of adenomatous polyps, PolypDx™. Come check…

MTI Launches New Product Website - PolypDx.com
News Posted On May 05, 2017

MTI Launches New Product Website - PolypDx.com

MTI is pleased to announce the launch of a new product website for our flagship product, PolypDx™. This website will provide important education and information on PolypDx™ for both patients and healthcare professionals, as we expand coverage of PolypDx™…

MTI featured at 2017 Canadian Medtech Mission to China
News Posted On Mar 25, 2017

MTI featured at 2017 Canadian Medtech Mission to China

From March 20 to 23, 2017, MTI's Dr. David Chang travelled to Beijing and Tianjin, China, as part of a delegation of medical device companies from Canada. PolypDx™ was featured as a leading potential diagnostic for the Chinese market. ...

MTI Granted Patent for PolypDx™ in Australia
News Posted On Feb 09, 2017

MTI Granted Patent for PolypDx™ in Australia

In early February, 2017, Metabolomic Technologies Inc. was granted a patent for its PolypDx™ technology by the Australian Patent Office. PolypDx™ received patent approval in Japan in September, 2015. Patents are also pending in the US, Canada, and…